Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 08/19/24 | DEF 14A | Definitive proxy statements |
|
50 | |
| 08/19/24 | 8-K | Current report filing |
|
   |
4 |
| 08/14/24 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
25 |
| 08/14/24 | 8-K | Current report filing |
|
|
5 |
| 08/09/24 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
51 | |
| 08/09/24 | 8-K | Current report filing |
|
|
2 |
| 07/24/24 | 8-K | Current report filing |
|
|
6 |
| 07/15/24 | EFFECT | Notice of Effectiveness |
|
1 | |
| 07/15/24 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
8 | |
| 07/11/24 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 |
